Melphalan hydrochloride and Pulmonary toxicity - a phase IV clinical study of FDA data

Summary:

Pulmonary toxicity is reported as a side effect among people who take Melphalan hydrochloride (melphalan hydrochloride), especially for people who are male, 2-9 old, have been taking the drug for < 1 month also take Methotrexate, and have Hodgkin's lymphoma.

The phase IV clinical study analyzes which people have Pulmonary toxicity when taking Melphalan hydrochloride. It is created by eHealthMe based on reports of 3,963 people who have side effects when taking Melphalan hydrochloride from the FDA, and is updated regularly.

What is Melphalan hydrochloride?

Melphalan hydrochloride has active ingredients of melphalan hydrochloride. eHealthMe is studying from 3,970 Melphalan hydrochloride users. Check the latest studies of Melphalan hydrochloride.

What is Pulmonary toxicity?

Pulmonary toxicity (side effects on the lungs) is found to be associated with 374 drugs and 465 conditions by eHealthMe. Check the latest studies of Pulmonary toxicity.

On Jul, 12, 2026

3,963 people reported to have side effects when taking Melphalan hydrochloride.
Among them, 11 people (0.28%) have Pulmonary toxicity.

Could Melphalan hydrochloride cause Pulmonary toxicity?

Among these 11 people:

How long have people been on Melphalan hydrochloride when they have Pulmonary toxicity? *

What is the gender of people who have Pulmonary toxicity when taking Melphalan hydrochloride? *

female: 25 %
male: 75 %

What is the age of people who have Pulmonary toxicity when taking Melphalan hydrochloride? *

What are other drugs people take besides Melphalan hydrochloride? *

What are other side effects people have besides Pulmonary toxicity? *

Ards (Acute Respiratory Distress Syndrome) (sudden failure of the respiratory (breathing) system): 4 people, 36.36%
Arrhythmias (irregular heartbeat): 4 people, 36.36%
Skin Toxicity (skin damage due to toxin/poison): 4 people, 36.36%
Mucosal Inflammation (infection of mucous membrane): 4 people, 36.36%
Hypothermia (body temperature drops below the required temperature for normal metabolism and body functions): 3 people, 27.27%
Pneumonia: 3 people, 27.27%
Device Related Infection: 3 people, 27.27%
Erythema Multiforme (a type of hypersensitivity reaction): 3 people, 27.27%
Gastrointestinal Haemorrhage (bleeding gastrointestinal tract): 3 people, 27.27%
Gastrointestinal Toxicity (damage to digestive tract by any substance): 3 people, 27.27%

What are the existing conditions these people have? *

Hodgkin's Lymphoma (cancer originating from white blood cells): 5 people, 45.45%
Acute Lymphocytic Leukemia (All) (cancer of the white blood cells characterized by excess lymphoblasts): 3 people, 27.27%
Malignant Melanoma (skin cancer rises from melancytes): 1 person, 9.09%
Bone Marrow Conditioning Regimen: 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Melphalan hydrochloride and have Pulmonary toxicity?

- Check whether Pulmonary toxicity is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Melphalan hydrochloride:

Melphalan hydrochloride (3,970 reports)

Browse all side effects of Melphalan hydrochloride:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Pulmonary toxicity:

Pulmonary toxicity (374 drugs)

Browse all the conditions that are associated with Pulmonary toxicity:

Pulmonary toxicity (465 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on melphalan hydrochloride (the active ingredients of Melphalan hydrochloride) and Melphalan hydrochloride (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.